Form 4: Avidity Biosciences Director Levin Exercises Options and Sells Shares Under 10b5-1 Plan

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 20, 2024, Arthur A. Levin, a director of Avidity Biosciences, exercised options to purchase 5,000 shares of common stock at a price of $1.24 per share.
• Simultaneously, Levin sold 5,000 shares of Avidity Biosciences common stock at a weighted-average price of $37.5901, with individual sales prices ranging from $37.05 to $38.10.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 26, 2023.
• Following these transactions, Levin directly owns 14,830 shares and indirectly owns 153,872 shares through a family trust.
• Levin also holds 23,323 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the director's confidence in the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Director selling activity could be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan is a common practice to avoid insider trading accusations.

Comparison to Industry Standards

• Corporate insiders frequently use 10b5-1 trading plans to manage their stock holdings, aligning with standard practices observed across publicly traded companies.
• The reported transactions are typical for directors and officers who receive stock options as part of their compensation packages.
• Comparable companies such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals also see similar insider trading activity disclosed through Form 4 filings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the director's selling activity, but the pre-arranged trading plan mitigates concerns.

Key Dates